A survey of UK general practitioners about depression, antidepressants and withdrawal: implementing the 2019 Public Health England report
Open accessThe DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index; 7 of the 26 sources its claims cite were checked for support.
Abstract
Background: In 2019, a literature review indicated that more than half of people who try to come off antidepressants experience withdrawal effects. Both the National Institute of Health and Care Excellence and the Royal College of Psychiatrists updated their positions in line with that review, and Public Health England published a 152-page report called Dependence and withdrawal associated with some prescribed medicines: an evidence review. The report made several recommendations relevant to general practice. Method: In order to facilitate implementation of these recommendations, an online survey was designed to explore United Kingdom general practitioner (GP) experiences, opinions, knowledge and needs in relation to depression, ADs and withdrawal. A total of 66 GPs had completed the survey when COVID-19 occurred. Results: In keeping with previous findings, this small sample of GPs had a predominantly psycho-social perspective on the causes of, and treatments for, depression. They broadly considered ADs effective for moderate/severe depression and ineffective for minimal/mild depression, for which they preferred psychological therapies and social prescribing. There was a marked lack of consistency in GPs’ knowledge about the incidence and duration of withdrawal effects. Only a minority (29%) felt their knowledge about withdrawal was ‘adequate’ and fewer (17%) believed this about their ‘Ability to distinguish between withdrawal effects and return of the original problem (e.g. depression)’. Two-thirds (68%) would like more training on these matters. Conclusion: It is hoped that even this small sample will be helpful when designing, and seeking funding for, GP training programmes, and when implementing the PHE recommendations for support services, based in the primary care system, for the millions of people contemplating or initiating withdrawal from ADs every year in the UK.
Overview
CoChat Summary
TL;DR
A survey of 66 UK general practitioners found predominantly psychosocial beliefs about depression, mixed knowledge about antidepressant withdrawal, and strong demand for more training. It was intended to help implement the 2019 Public Health England recommendations, but recruitment stopped because of COVID-19 and the sample was very small.
Key findings
- Most GPs (53/66; 80%) thought social causes contributed more than bio-genetic causes to depression; the most endorsed causes were child abuse/neglect and violence/rape in adulthood, while genetic predisposition and chemical imbalance were least endorsed.
- GPs viewed antidepressants as much more effective for moderate/severe depression (25% “very effective,” 68% “somewhat effective”) than minimal/mild depression (5% “very effective,” 28% “somewhat effective,” 31% “not at all effective”); for minimal/mild depression, antidepressants were the 7th most endorsed treatment option.
- Withdrawal knowledge was inconsistent: 27%, 24%, and 24% estimated that no more than 10% of patients experience withdrawal after 3 months, 1 year, and 3 years respectively, and 40% thought withdrawal was experienced by no more than 30% even after 3 years. Only 29% rated their knowledge about withdrawal as “adequate,” 14% rated their ability to distinguish withdrawal from relapse as “adequate,” and 68% wanted more training.
- Most GPs (83%) thought the current antidepressant prescribing rate was too high; 77% said they “always” or “most of the time” inform patients about possible withdrawal effects; all 56 who answered the services question ticked NHS provision, with 48% also endorsing NGOs/voluntary sector.
Methods
- An online questionnaire was designed from the research literature, trialled on three GPs, and advertised via a BMJ article and social media, including the “Resilient GP” Facebook group.
- Between 7 February and 10 March 2020, 66 UK GPs completed the survey; recruitment ceased when COVID-19 occurred.
- Quantitative multiple-choice data were reported as descriptive statistics without demographic analysis due to small numbers; open-ended responses were reported as numbers of similar or identical responses.
Limitations
- The paper states the very small sample size, representing only about 0.15% of GPs in England and effectively none from the rest of the UK, would normally prohibit journal submission; it also states the most likely bias is disproportionate inclusion of GPs with particular interest in and knowledge of antidepressants and withdrawal, so findings on psychosocial perspectives should be received with caution, and perceived inadequacy or inaccurate beliefs might be even more pronounced in a more representative sample.
- The authors note that GPs’ reports of informing patients about withdrawal may reflect social desirability rather than actual practice.
- Evident from the text: the sample was self-selected via BMJ and social media, the analysis is descriptive only with no inferential or demographic adjustment, and three participants left some questions unanswered.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
5 Valid · 0 Not valid · 12 Not checked · 58 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Three recent systematic reviews have, however, indicated that these are gross underestimates.21–23”
§ A survey of UK general practitioners about depression, antidepressants and withdrawal: implementing the 2019 Public Health England report > Introduction
What the sources say
- Supportedcites [21] Davies J Read J A systematic review into the incidence, severity and duration of antidepressant withdrawal effects: are guidelines evidence-based? Addict Behav 2019; 97: 111– 121. 30292574 source
The Introduction quotes the NICE estimate of about one week and the US estimate of one to two weeks. Sections 3.4 and 4.4 report that a significant proportion of people experience withdrawal for more than two weeks and that its duration is higher than guidelines acknowledge. This paper is one of the reviews cited, not the source for the count of three. (LLM, conf=0.93)
- Partly supportedcites [22] Fava G Gatti A Belaise C, et al Withdrawal symptoms after selective serotonin reuptake inhibitors discontinuation: a systematic review. Psychother Psychosom 2015; 84: 72– 81. 25721705 sourceExperimental — accuracy not yet measured
The Discussion (page unavailable) says SSRI withdrawal typically lasts a few weeks but reports symptoms persisting up to one year, supporting the point that short duration estimates can miss prolonged cases. It does not compare its findings with NICE or US guideline estimates or establish that those estimates are gross underestimates. (LLM, conf=0.83)
- Partly supportedcites [23] Fava G Benasi G Lucente M, et al Withdrawal symptoms after serotonin-noradrenaline reuptake inhibitor discontinuation: systematic review. Psychother Psychosom 2018; 87: 195– 203. 30016772 sourceExperimental — accuracy not yet measured
The Discussion (p. 5) says SNRI withdrawal symptoms typically lasted a few weeks, but longer episodes occurred; the Results (p. 5) report a few venlafaxine cases lasting months or years. This supports the point that short duration estimates can underestimate some cases, but the paper does not compare its findings with NICE or US guideline estimates or establish that those estimates are gross underestimates overall. (LLM, conf=0.84)
hedged- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“For example, UK data on 189,851 general practice patients revealed that a doubling of prescribing over 8 years was explained not by increases in new prescriptions but a doubling of the number of prescriptions per patient.18”
§ A survey of UK general practitioners about depression, antidepressants and withdrawal: implementing the 2019 Public Health England report > Introduction
What the sources say
- Partly supportedcites [18] Moore M Yuen H Dunn N, et al Explaining the rise in antidepressant prescribing: a descriptive study using the general practice research database. Br Med J 2009; 339: b3999. PMC2762496 19833707 sourceExperimental — accuracy not yet measured
Our copy confirms the cohort size and the explanatory mechanism: the Results (p. 1) state that 189,851 people in the GPRD had a first episode of depression, that 'antidepressant prescribing nearly doubled during the study period—the average number of prescriptions issued per patient increased from 2.8 in 1993 to 5.6 in 2004', and the Conclusions attribute the rise to more patients on long-term medication rather than to incidence of new cases, a lower treatment threshold, or a larger proportion of new cases being prescribed antidepressants. However, the time frame is wrong: the doubling the paper reports spans 1993–2005 (13 years; per-patient doubling 1993–2004), not 8 years — the 'eight year study' in our copy belongs to a Canadian study (ref 16) cited only for comparison in 'Strengths and limitations'. Also, the 189,851 are general practice patients diagnosed with depression, not the practice population as a whole (1.7 million registered patients in the 170 stable practices). (LLM, conf=0.78)
plainstates a causen = 189,851- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“This contrasts with the 56% average rate identified (for all lengths of treatments combined) by the latest review.21”
§ A survey of UK general practitioners about depression, antidepressants and withdrawal: implementing the 2019 Public Health England report > Discussion > Implementing PHE recommendations
What the sources say
- Supportedcites [21] Davies J Read J A systematic review into the incidence, severity and duration of antidepressant withdrawal effects: are guidelines evidence-based? Addict Behav 2019; 97: 111– 121. 30292574 source
The review's Incidence section (3.2) reports the pooled figure the citing sentence attributes to it: 'The combined median of all studies was 55%, with a weighted average of 55.7% (2258/4052)', which Table 1 also gives as the WEIGHTED AVERAGE — 56% is a straightforward rounding of 55.7%. The estimate combines all 14 usable datasets irrespective of treatment length (Table 1 spans 6 weeks to 8 months and longer, including real-world surveys of broad duration ranges), so the parenthetical 'for all lengths of treatments combined' is a fair paraphrase of the pooled average; the paper's own Limitations note that duration differences were not factored in separately rather than that the estimate is restricted to one length. The Excluded studies section even gives a slightly higher 56.5% had the three outlier studies been included, so the direction of the number is not overstated. (LLM, conf=0.85)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Evidence is emerging, however, that suggests that antidepressants, like benzodiazepines, should usually be tapered very slowly, often over several months or longer (but tailored to the individual) not 2–4 weeks as suggested by many guidelines.35,36”
§ A survey of UK general practitioners about depression, antidepressants and withdrawal: implementing the 2019 Public Health England report > Discussion > Implementing PHE recommendations
What the sources say
- Not checked yetcites [35] Groot PC van Os J Antidepressant tapering strips to help people come off medication more safely. Psychosis 2018; 10: 142– 145. source
- Partly supportedcites [36] Horowitz M Taylor D Tapering of SSRI treatment to mitigate withdrawal symptoms. Lancet Psychiatry 2019; 6: 538– 546. 30850328 sourceExperimental — accuracy not yet measured
The paper’s “Tapering SSRIs” discussion says several guidelines recommend two-to-four-week tapers, while its discussion of longer tapering reports better outcomes with tapers lasting months. It also compares SSRI tapering with benzodiazepine withdrawal regimens and describes adjusting reductions to the individual. Its recommendation and supporting evidence focus on SSRIs, however, rather than establishing that antidepressants generally should usually be tapered over several months or longer. (LLM, conf=0.85)
hedged- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Every source the paper cites for this claim was checked and supports it.
In the paper
“In a large online survey, self-reported efficacy was independently predicted, after controlling for a range of other psycho-social variables, by both the amount of information about ADs offered by the prescriber and the perceived quality of the relationship between prescriber and patient.38”
§ A survey of UK general practitioners about depression, antidepressants and withdrawal: implementing the 2019 Public Health England report > Discussion > Information given to patients
What the sources say
- Supportedcites [38] Read J Gibson K Cartwright C, et al Understanding the non-pharmacological correlates of self-reported efficacy of antidepressants. Acta Psychiatr Scand 2015; 131: 434– 445. 25572791 PMC4600242 source
Split into 2 atoms — 2 confirmed, 0 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
31 more claims
Create a free account to see all 75 claims and to verify the 18 references still open.
- Probably not a substantial claim. 20
- It may state two separate claims as one. 25
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Previous research has identified that GPs do not feel confident in their knowledge of helping patients to come off antidepressants49”
The cited source says what the claim attributes to it.
In the citing paper
“A lack of sufficient information on discontinuation was also identified as a key issue for GPs.27,49”
In the citing paper
“a recent survey of UK general practitioners (GPs) (albeit with a curtailed sample size due to Covid-19) just reported that although there was ‘a marked lack of consistency in GPs’ knowledge about the incidence and duration of withdrawal effects’ two-thirds said they would welcome more training on these matters.59”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ A survey of UK general practitioners about depression, antidepressants and withdrawal: implementing the 2019 Public Health England report > Abstract > Results:
“fewer (17%) believed this about their ‘Ability to distinguish between withdrawal effects and return of the original problem (e.g. depression)’”
§ A survey of UK general practitioners about depression, antidepressants and withdrawal: implementing the 2019 Public Health England report > Results > Withdrawal: beliefs, knowledge and training needs
“| ‘Ability to distinguish between withdrawal effects and return of the original problem (e.g. depression)’ | 14% | 56% | 19% | 8% | 3% |”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
“The most frequently endorsed of the five options were ‘every 3 months’ (36%) and ‘every 6 months’ (36%), followed by ‘once a year’ (17%), once a month (11%) and ‘never’ (3%).”
§ A survey of UK general practitioners about depression, antidepressants and withdrawal: implementing the 2019 Public Health England report > Results > Clinical practice
Reported 100 · recomputed 103
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
“| Financial problems | 71% | 18% | 2% | | | 1.30 |”
§ A survey of UK general practitioners about depression, antidepressants and withdrawal: implementing the 2019 Public Health England report > Results > Causal beliefs
Reported 100 · recomputed 91
Citations
Cites
Cipriani, A., Furukawa, T. A., Salanti, G., Chaimani, A., Atkinson, L. Z., Ogawa, Y., Leucht, S., Ruhe, H. G., Turner, E. H., Higgins, J. P. T., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(17)32802-7 · Cited by 3,541 · cited 1×
“An online questionnaire was designed, based primarily on the research literature discussed previously, 1,4–11, 18– 23 The questionnaire was trialled on three GPs, and minor amendments made.”
Kirsch, I., Deacon, B. J., Huedo-Medina, T. B., Scoboria, A., Moore, T. J., & Johnson, B. T. (2008) · PLoS Medicine · doi:10.1371/journal.pmed.0050045 · Cited by 2,442 · cited 1×
“The most common theme was increasing social connectedness/reducing isolation (15), followed by reducing inequality (9), improving children’s wellbeing/safety (8) and improving work culture (7).”
Selective publication of antidepressant trials and its influence on apparent efficacy
Turner, E. H., Matthews, A. M., Linardatos, E., Tell, R. A., & Rosenthal, R. (2008) · New England Journal of Medicine · doi:10.1056/nejmsa065779 · Cited by 2,435 · cited 2×
“CAHMS is woeful in most areas, the waits for IAPT ridiculous, the CMHTs in crisis and so as GPs we are left trying to sort these vary complex patients in 10 min appointments as well as deal with their physical health, carers and families.”
Are we all less risky and more skillful than our fellow drivers?
Svenson, O. (1981) · Acta Psychologica · doi:10.1016/0001-6918(81)90005-6 · Cited by 1,969 · cited 1×
“44 Another potential explanation, not considered by our survey, is that GPs prescribing decisions are led by whether patients present their difficulties in terms of symptoms or psycho-social events.”
Fava, G. A., Gatti, A., Belaise, C., Guidi, J., & Offidani, E. (2015) · Psychotherapy and Psychosomatics · doi:10.1159/000370338 · Cited by 436
Davies, J., & Read, J. (2019) · Addictive Behaviors · doi:10.1016/j.addbeh.2018.08.027 · Cited by 387 · cited 2×
“20 21–23 The most recent of the three reviews was undertaken for the All Party Parliamentary Group for Prescribed Drug Dependence in the UK, 21 to inform an enquiry by Public Health England (PHE).”
Self-citationJakobsen, J. C., Katakam, K. K., Schou, A., Hellmuth, S. G., Stallknecht, S. E., Leth-Møller, K., Iversen, M., Banke, M. B., Petersen, I. J., Klingenberg, S. L., et al. (2017) · BMC Psychiatry · doi:10.1186/s12888-016-1173-2 · Cited by 366 · cited 1×
“10 14–17 In this context, attempts to understand the per-petually increasing prescription rates began to focus on increases in repeat prescriptions.”
Adverse reactions to antidepressants
Uher, R., Farmer, A., Henigsberg, N., Rietschel, M., Mors, O., Maier, W., Kozel, D., Hauser, J., Souery, D., Placentino, A., et al. (2009) · British Journal of Psychiatry · doi:10.1192/bjp.bp.108.061960 · Cited by 302
Moore, M., Yuen, H. M., Dunn, N., Mullee, M. A., Maskell, J., & Kendrick, T. (2009) · BMJ · doi:10.1136/bmj.b3999 · Cited by 287 · cited 2×
“18 Such findings raised the issue of the withdrawal effects of ADs, until recently a somewhat taboo topic.”
Antidepressant discontinuation reactions: Are preventable and simple to treat
Haddad, P., Lejoyeux, M., & Young, A. (1998) · BMJ · doi:10.1136/bmj.316.7138.1105 · Cited by 286
Tapering of SSRI treatment to mitigate withdrawal symptoms
Horowitz, M. A., & Taylor, D. (2019) · The Lancet Psychiatry · doi:10.1016/s2215-0366(19)30032-x · Cited by 280
Let them eat Prozac: the unhealthy relationship between the pharmaceutical industry and depression
(2004) · Choice Reviews Online · doi:10.5860/choice.42-0979 · Cited by 248
Antidepressant Use Among Persons Aged 12 and Over:United States,2011-2014.
Pratt, L. A., Brody, D. J., & Gu, Q. (2017) · PubMed · Cited by 246
Antidepressants versus placebo in major depression: an overview
Khan, A., & Brown, W. A. (2015) · World Psychiatry · doi:10.1002/wps.20241 · Cited by 235 · cited 3×
“The most common theme was increasing social connectedness/reducing isolation (15), followed by reducing inequality (9), improving children’s wellbeing/safety (8) and improving work culture (7).”
Fava, G. A., Benasi, G., Lucente, M., Offidani, E., Cosci, F., & Guidi, J. (2018) · Psychotherapy and Psychosomatics · doi:10.1159/000491524 · Cited by 209 · cited 1×
“An online questionnaire was designed, based primarily on the research literature discussed previously, 1,4–11, 18– 23 The questionnaire was trialled on three GPs, and minor amendments made.”
Read, J., & Williams, J. (2018) · Current Drug Safety · doi:10.2174/1574886313666180605095130 · Cited by 175 · cited 1×
“IPS, individual placement support; NHS, National Health Service. stark contrast to the two largest surveys ever conducted, of over 1800 and over 1400 AD recipients, 16,38 in which less than 2% reported being told anything about withdrawal effects by the prescribing doctor.”
Self-citationDeadly medicines and organised crime: How big pharma has corrupted healthcare
Dickinson, J. A. (2014) · Europe PMC (PubMed Central) · Cited by 171
Dowrick, C., & Frances, A. (2013) · BMJ · doi:10.1136/bmj.f7140 · Cited by 167
Self-citationRead, J., Cartwright, C., & Gibson, K. (2014) · Psychiatry Research · doi:10.1016/j.psychres.2014.01.042 · Cited by 150 · cited 1×
“The most common theme was increasing social connectedness/reducing isolation (15), followed by reducing inequality (9), improving children’s wellbeing/safety (8) and improving work culture (7).”
Self-citationReview: problems associated with long-term treatment with selective serotonin reuptake inhibitors
Moret, C., Isaac, M., & Briley, M. (2009) · Journal of Psychopharmacology · doi:10.1177/0269881108093582 · Cited by 135
Are placebo controls necessary to test new antidepressants and anxiolytics?
Khan, A., Khan, S., & Brown, W. A. (2002) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145702002912 · Cited by 130 · cited 5×
“Of the 63 who responded, 52% ticked ‘Always’, 25% ticked ‘Most of the time’, 14% ‘About half the time’, 5% ‘Occasionally’ and 3% ‘Never’.”
InfluentialDependence and withdrawal associated with some prescribed medicines. An evidence review.
Taylor, S., Annand, F., Burkinshaw, P., Greaves, F., Kelleher, M., Knight, J., Perkins, C., Tran, A., White, M. J., & Marsden, J. (2019) · Cited by 86
Managing antidepressant discontinuation: a systematic review
Maund, E., Stuart, B., Moore, M., Dowrick, C., Geraghty, A. W. A., Dawson, S., & Kendrick, T. (2019) · The Annals of Family Medicine · doi:10.1370/afm.2336 · Cited by 82
Self-citationAntidepressant tapering strips to help people come off medication more safely
Groot, P. C., & van Os, J. (2018) · Psychosis · doi:10.1080/17522439.2018.1469163 · Cited by 55
Karasz, A., Dowrick, C., Byng, R., Buszewicz, M., Ferri, L., Hartman, T. C. O., van Dulmen, S., van Weel-Baumgarten, E., & Reeve, J. (2012) · British Journal of General Practice · doi:10.3399/bjgp12x616373 · Cited by 49 · cited 1×
“45 Implementing PHE recommendations This very small sample of GPs reports a very wide range of beliefs about how many people experience withdrawal symptoms (Table 5), and about how long people need to successfully come off ADs We are overtreating depression with medication instead of improving…”
Self-citationPilkington, P. D., Reavley, N. J., & Jorm, A. F. (2013) · Journal of Affective Disorders · doi:10.1016/j.jad.2013.04.019 · Cited by 47
Patient-Centered Perspectives on Antidepressant Use: A Narrative Review
Gibson, K., Cartwright, C., & Read, J. (2014) · International Journal of Mental Health · doi:10.2753/imh0020-7411430105 · Cited by 46
Self-citationDowrick, C. F. (2009) · Oxford University Press eBooks · doi:10.1093/med/9780199545292.001.1 · Cited by 46
Self-citationRead, J., Gee, A., Diggle, J., & Butler, H. (2017) · Psychiatry Research · doi:10.1016/j.psychres.2017.07.003 · Cited by 44 · cited 1×
“10 14–17 In this context, attempts to understand the per-petually increasing prescription rates began to focus on increases in repeat prescriptions.”
Self-citationRead, J., Cartwright, C., Gibson, K., Shiels, C., & Haslam, N. (2014) · Journal of Affective Disorders · doi:10.1016/j.jad.2014.06.010 · Cited by 42 · cited 1×
“42,43 These GPs do believe there is a role for ADs, but only for moderate/severe depression.”
Self-citationNICE updates antidepressant guidelines to reflect severity and length of withdrawal symptoms
Iacobucci, G. (2019) · BMJ · doi:10.1136/bmj.l6103 · Cited by 42
Hagmayer, Y., & Engelmann, N. (2014) · Frontiers in Psychology · doi:10.3389/fpsyg.2014.01303 · Cited by 38 · cited 1×
“These beliefs are consistent with previous studies of GPs, 33,34 and with the public’s causal beliefs, 40,41 including people taking ADs.”
Beliefs of people taking antidepressants about the causes of their own depression
Read, J., Cartwright, C., Gibson, K., Shiels, C., & Magliano, L. (2015) · Journal of Affective Disorders · doi:10.1016/j.jad.2014.11.009 · Cited by 37 · cited 1×
“42,43 These GPs do believe there is a role for ADs, but only for moderate/severe depression.”
Self-citationA literature review and meta‐analysis of drug company–funded mental health websites
Read, J., & Cain, A. (2013) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.12146 · Cited by 27 · cited 1×
“31,32 Overall, however, this small sample of GPs adopts a predominantly psycho-social perspective on the causes of, and solutions to, depression.”
Self-citationKendrick, T., Geraghty, A. W. A., Bowers, H., Stuart, B., Leydon, G., May, C., Yao, G., O’Brien, W., Glowacka, M., Holley, S., et al. (2020) · Trials · doi:10.1186/s13063-020-04338-7 · Cited by 26 · cited 1×
“…(COVID-19), however, with no further recruitment possible, or appropriate, we hoped our data, however limited, may be helpful to government officials, professional bodies, and researchers, 47 planning for implementation of the hugely important PHE Report once these circumstances abate.”
Self-citationAntidepressants: misnamed and misrepresented
Moncrieff, J. (2015) · World Psychiatry · doi:10.1002/wps.20243 · Cited by 21 · cited 1×
“The most common theme was increasing social connectedness/reducing isolation (15), followed by reducing inequality (9), improving children’s wellbeing/safety (8) and improving work culture (7).”
Understanding the non‐pharmacological correlates of self‐reported efficacy of antidepressants
Read, J., Gibson, K., Cartwright, C., Shiels, C., Dowrick, C., & Gabbay, M. (2015) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.12390 · Cited by 20 · cited 2×
“IPS, individual placement support; NHS, National Health Service. stark contrast to the two largest surveys ever conducted, of over 1800 and over 1400 AD recipients, 16,38 in which less than 2% reported being told anything about withdrawal effects by the prescribing doctor.”
Self-citationWilson, J., & Read, J. (2001) · Family Practice · doi:10.1093/fampra/18.1.84 · Cited by 18
Self-citationAntidepressant drugs consumption, 2000 and 2015 (or nearest year)
(2017) · Health at a glance · doi:10.1787/health_glance-2017-graph181-en · Cited by 17
Relabeling the Medications We Call Antidepressants
Antonuccio, D. O., & Healy, D. T. (2012) · Scientifica · doi:10.6064/2012/965908 · Cited by 16 · cited 1×
“An online questionnaire was designed, based primarily on the research literature discussed previously, 1,4–11, 18– 23 The questionnaire was trialled on three GPs, and minor amendments made.”
The pharmaceutical industry and the internet: Are drug company funded depression websites biased?
Wattignar, S., & Read, J. (2009) · Journal of Mental Health · doi:10.1080/09638230902968183 · Cited by 10 · cited 1×
“31,32 Overall, however, this small sample of GPs adopts a predominantly psycho-social perspective on the causes of, and solutions to, depression.”
Self-citationAntidepressant withdrawal. . . five minutes with John Read
Mahase, E. (2020) · BMJ · doi:10.1136/bmj.m510 · Cited by 2
Research works printed but not linked: 2
- Royal College of Psychiatrists. Position statement on antidepressants and depression, PS04/19. London: R.C.P, 2019.
- Ogden E New Zealand GPs: their perspectives on depression and antidepressants. Unpublished Doctoral Thesis, University of Auckland, NZ, 2016.
Cited by
Surging trends in prescriptions and costs of antidepressants in England amid COVID-19
Rabeea, S. A., Merchant, H. A., Khan, M. U., Kow, C. S., & Hasan, S. S. (2021) · DARU Journal of Pharmaceutical Sciences · doi:10.1007/s40199-021-00390-z · Cited by 123
Guy, A., Brown, M., Lewis, S., & Horowitz, M. (2020) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125320967183 · Cited by 77
White, E., Read, J., & Julo, S. (2021) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125320981174 · Cited by 63
Self-citationAng, B., Horowitz, M. A., & Moncrieff, J. (2022) · SSM - Mental Health · doi:10.1016/j.ssmmh.2022.100098 · Cited by 57
Successful use of tapering strips for hyperbolic reduction of antidepressant dose: a cohort study
Groot, P. C., & van Os, J. (2021) · Therapeutic Advances in Psychopharmacology · doi:10.1177/20451253211039327 · Cited by 38
Metadata
- Authors
- Read, J., Renton, J., Harrop, C., Geekie, J., & Dowrick, C.
- Affiliations
- University of East London (GB)
- West London Mental Health NHS Trust (GB)
- West London NHS Trust, London, UK
- NHS Lothian (GB)
- University of Liverpool (GB)
- Corresponding author
- Read, John
- Venue
- Therapeutic Advances in Psychopharmacology
- Publisher
- SAGE Publications
- Published
- 2020-01
- Volume
- 10
- Pages
- 2045125320950124-2045125320950124
- ISSN
- 2045-1253 (ISSN-L)
- 2045-1261
- PMC
- PMC7457636
- OpenAlex
- W3080737126
- Cited by
- 43
- References
- 41
- Citations by year
- 2026: 1 · 2025: 4 · 2024: 6 · 2023: 8 · 2022: 6 · 2021: 17 · 2020: 1
- FWCI
- 4.79
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Therapeutic Advances in Psychopharmacology (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- UEL Research Repository (University of East London) (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Health Sciences › Medicine › Psychiatry and Mental health › Mental Health Treatment and Access
- Health Sciences › Medicine › Geriatrics and Gerontology › Pharmaceutical Practices and Patient Outcomes
- Keywords
- antidepressant discontinuation, antidepressants, depression, general practitioners, withdrawal effects, implementation, general practice training, mild depression, psychotherapy, social prescribing, primary care
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-07, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-07 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol and qwen3.8-omni-flash).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.